Strategic Initiative
Slingshot members are tracking this corporate initiative:
Teva (TEVA) and South Korean Celltrion Enter into Exclusive Partnership to Commercialize Biosimilars to Rituxan and Herceptin in the U.S and Canada
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Oct 06, 2016 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2019
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Exclusive Partnership, Commercialize, Biosimilars, Rituxan, Herceptin, Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Her2-overexpressing Breast Cancer, Her2-overexpressing Metastatic Gastric, Gastroesophageal Junction Adenocarcinoma
